Skip to main content

Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid

Osteoporosis International volume 21, pages 1585–1590 (2010)Cite this article

Abstract

Summary

Urinary deoxypyridinoline (DPD) level was associated with prevalent vertebral fractures in glucocorticoid (GC)-treated postmenopausal women independently of lumbar spine bone mineral density (BMD).

Introduction

Bone metabolic indices are the potential predictors of bone fragility. However, their diagnostic efficiency for identifying the risk of GC-induced vertebral fractures is still unclear. We therefore evaluated whether bone metabolic indices would assess the risk of vertebral fractures in GC-treated women.

Methods

One hundred seventy-five women treated with GC for more than 6 months were enrolled in this study.

Results

Both premenopausal and postmenopausal women with vertebral fractures had significantly higher urinary DPD levels than those without vertebral fractures. When multivariable logistic regression analysis was performed with the presence of vertebral fractures as a dependent variable and each of DPD or osteocalcin level adjusted for age, weight, height, current and maximum doses of GC, duration of GC treatment, as well as lumbar spine BMD as an independent variable, DPD level was identified as a factor associated with the presence of vertebral fractures in postmenopausal women but not in premenopausal women.

Conclusion

Urinary DPD level was significantly associated with prevalent vertebral fractures in GC-treated postmenopausal women independently of lumbar spine BMD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthr Rheum 48:3224–3229

    Article  Google Scholar 

  2. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000

    Article  PubMed  Google Scholar 

  3. Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323–328

    Article  CAS  PubMed  Google Scholar 

  4. Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  PubMed  Google Scholar 

  5. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HAP, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899

    Article  PubMed  Google Scholar 

  6. Manelli F, Giustina A (2000) Glucocorticoid-induced osteoporosis. Trend Endocrinol Metab 11:79–85

    Article  CAS  Google Scholar 

  7. Kaltsas G, Manetti L, Grossman AB (2002) Osteoporosis in Cushing’s syndrome. Front Horm Res 30:60–72

    Article  CAS  PubMed  Google Scholar 

  8. Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80:2859–2865

    Article  CAS  PubMed  Google Scholar 

  9. Francucci CM, Pantanetti P, Garrapa GG, Massi F, Arnaldi G, Mantero F (2002) Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma. Clin Endocrinol 57:587–593

    Article  CAS  Google Scholar 

  10. Vestergaard P, Lindholm J, Jorgensen JOL, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen LO, Feldt-Rasmussen U, Mosekilde L (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146:51–56

    Article  CAS  PubMed  Google Scholar 

  11. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research. J Bone Mineral Metab 23:105–109

    Article  Google Scholar 

  12. Kaji H, Yamauchi M, Chihara K, Sugimoto T (2006) The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 53:27–34

    Article  CAS  PubMed  Google Scholar 

  13. Hayashi K, Yamamoto M, Murakawa Y, Yamauchi M, Kaji H, Yamaguchi T, Sugimoto T (2009) Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int 20:1889–1894

    Article  CAS  PubMed  Google Scholar 

  14. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN (2000) Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 160:2917–2922

    Article  CAS  PubMed  Google Scholar 

  15. Kaji H, Tobimatsu T, Naito J, Iu MF, Yamauchi M, Sugimoto T, Chihara K (2006) Body composition and vertebral fracture risk in female patients treated with glucocortiocid. Osteoporos Int 17:627–633

    Article  CAS  PubMed  Google Scholar 

  16. NIH Consensus Development Panel on Osteoporosis Prevention (2001) Osteoporosis prevention, diagnosis, and the therapy. JAMA 285:785–795

    Article  Google Scholar 

  17. Kaji H, Yamauchi M, Chihara K, Sugimoto T (2008) Glucocorticoid excess affects cortical bone geometry in premenopausal, but not postmenopausal, women. Calcif Tissue Int 82:182–190

    Article  CAS  PubMed  Google Scholar 

  18. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526–1536

    Article  CAS  PubMed  Google Scholar 

  19. Ton FN, Gunawardene SC, Lee H, Neer RM (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464–470

    Article  CAS  PubMed  Google Scholar 

  20. Chiodini I, Carnevale V, Torlontano M, Fusilli S, Guglielmi G, Pileri M, Modoni S, Giorgio AD, Liuzzi A, Cammisa M, Trischitta V, Scillitani A (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing’s syndrome. J Clin Endocrinol Metab 83:1863–1867

    Article  CAS  PubMed  Google Scholar 

  21. Godang K, Ueland T, Bollerslev J (1999) Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing’s syndrome. Eur J Endocrinol 141:126–131

    Article  CAS  PubMed  Google Scholar 

  22. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP (1991) The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72:382–386

    Article  CAS  PubMed  Google Scholar 

  23. Kaji H, Nomura R, Yamauchi M, Chihara K, Sugimoto T (2006) The usefulness of bone metabolic indices for the prediction of changes in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism. Horm Metab Res 38:411–416

    Article  CAS  PubMed  Google Scholar 

  24. Smith-Bindman R, Cummings SR, Steiger P, Genant HK (1991) A comparison of morphometric definitions of vertebral fractures. J Bone Miner Res 6:25–34

    Article  CAS  PubMed  Google Scholar 

  25. Dovio A, Perazzolo L, Osella G, Entura M, Termine A, Milano E, Bertolotto A, Angeli A (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89:4923–4928

    Article  CAS  PubMed  Google Scholar 

  26. Kuroki Y, Kaji H, Kawano S, Kanda F, Takai Y, Kajikawa M, Sugimoto T (2008) Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 26:271–278

    Article  CAS  PubMed  Google Scholar 

  27. Minisola S, Del Fiacco R, Piemonte S, Iorio M, Mascia ML, Fidanza F, Ciproani C, Raso I, Porfiri ML, Francucci CM, D’Erasmo E, Romagnoli E (2008) Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 32(7 Suppl):28–32

    Google Scholar 

Download references

Conflicts of interest

None.

Author information

Affiliations

  1. Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    H. Kaji

  2. Division of Cellular and Molecular Medicine, Department of Physiology and Cellular Biology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    H. Kaji

  3. Internal Medicine 1, Shimane University Faculty of Medicine, Matsue, Shimane, Japan

    M. Yamauchi, T. Yamaguchi & T. Sugimoto

Authors
  1. H. Kaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Kaji.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kaji, H., Yamauchi, M., Yamaguchi, T. et al. Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid. Osteoporos Int 21, 1585–1590 (2010). https://doi.org/10.1007/s00198-009-1108-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1108-6

Keywords

  • Bone metabolic index
  • Fracture
  • Glucocorticoid
  • Osteoporosis